Journal article icon

Journal article

Low risk of recurrence following artesunate-Sulphadoxine-pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan

Abstract:

Background

First-line schizontocidal treatment for uncomplicated malaria in the Republic of the Sudan is artesunate (total dose 12 mg/kg) plus Sulphadoxine/pyrimethamine (25/1.25 mg/kg) (AS/SP). Patients with Plasmodium vivax are also treated with 14 days primaquine (total dose 3.5 mg/kg) (PQ). The aim of this study was to assess the efficacy of the national policy.

Methods

Patients above 1 year, with microscopy-confirmed, Plasmodium falciparum and/or P. vivax mal...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1186/s12936-018-2266-9

Authors


Expand authors...
Bill and Melinda Gates Foundation More from this funder
the Australian Department of Foreign Affairs and Trade More from this funder
More from this funder
Grant:
Senior Fellowship in Clinical Science, 200909
Publisher:
BioMed Central Publisher's website
Journal:
Malaria Journal Journal website
Volume:
17
Issue:
1
Pages:
117
Publication date:
2018-03-05
Acceptance date:
2018-03-08
DOI:
EISSN:
1475-2875
Pubs id:
pubs:831391
URN:
uri:c7918e8f-3819-4370-b480-e2bf71e9f234
UUID:
uuid:c7918e8f-3819-4370-b480-e2bf71e9f234
Local pid:
pubs:831391
Language:
English
Keywords:

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP